Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New inhaled sedative could change ICU care

NCT ID NCT05312385

Symptom relief Sponsor: Sedana Medical Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether an inhaled anesthetic gas, isoflurane, given through a special device (Sedaconda ACD-S), works better than the standard IV drug propofol for keeping ICU patients comfortably sedated while on a breathing machine. The trial involved 277 adults expected to need sedation for more than 12 hours. Researchers measured how often sedation stayed in the target range and whether opioid use could be reduced.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
isoflurane (inhaled anesthetic gas)
What this could lead to
If it works, this could offer a new way to sedate ICU patients on ventilators that may reduce opioid use compared to current standard care.
What could go wrong
This is a completed Phase 3 trial, but results are not yet published. The benefit over propofol may be small, and inhaled isoflurane requires special equipment and monitoring.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

277 people

The number who actually took part.

Started

Apr 2022

Finished

Oct 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults ≥18 years of age; * Patients who are anticipated to require \>12 hours of invasive mechanical ventilation and continuous sedation in the ICU; and * Receipt of continuous sedation due to clinical need for sedation to RASS \<0. Exclusion Criteria: * Need for RASS -5; * Sedation for invasive mechanical ventilation immediately prior to Baseline for \>72 hours; * Severe neurological condition before ICU admission that causes the patient to lack ability to participate in the study (ie, unable to be assessed for RASS and CPOT); * Ventilator tidal volume \<200 or \>1000 mL at Baseline; * Need for extracorporeal membrane oxygenation (ECMO), extracorporeal CO2 removal (ECCO2R), high frequency oscillation ventilation (HFOV), or high frequency percussive ventilation (HFPV) at Screening; * Comfort care only (end of life care); * Contraindication to propofol or isoflurane; * Known or family history of MH; * Severe hemodynamic compromise, defined as the need for norepinephrine ≥0.3 mcg/kg/min (or equivalent vasopressor dose) to maintain blood pressure within acceptable range, assumed to be mean arterial pressure ≥65 mmHg unless prescribed clinically; * Allergy to isoflurane or propofol, or have propofol infusion syndrome. * History of ventricular tachycardia/Long QT Syndrome; * Requirement of IV benzodiazepine or barbiturate administration for seizures or dependencies, including alcohol withdrawal * Neuromuscular disease that impairs spontaneous ventilation (eg, C5 or higher spinal cord injury, amyotrophic lateral sclerosis, etc); * Concurrent enrollment in another study that, in the Investigator's opinion, would impact the patient's safety or assessments of this study; * Participation in other study involving investigational drug(s) or devices(s) within 30 days prior to Randomization; * Anticipated requirement of treatment with continuous infusion of a neuromuscular blocking agent for \>4 hours; * Female patients who are pregnant or breast-feeding; * Imperative need for continuous active humidification through mechanical ventilation circuit; * Attending physician's refusal to include the patient; or * Inability to obtain informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Sedation are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Sedation

Contacts and locations

Locations

  • Emory University

    Atlanta, Georgia, 30322, United States

  • Houston Methodist Hospital

    Houston, Texas, 77030, United States

  • Intermountain Health Care Health Services

    Salt Lake City, Utah, 84111, United States

  • MD Anderson Cancer Center

    Houston, Texas, 77030, United States

  • Mayo Clinic

    Rochester, Minnesota, 55905, United States

  • The Brigham and Women´s Hospital

    Boston, Massachusetts, 02115, United States

  • The Cleveland Clinic Foundation

    Cleveland, Ohio, 44195, United States

  • Tufts Medical Center

    Boston, Massachusetts, 02111, United States

  • University of Chicago

    Chicago, Illinois, 60637, United States

  • University of Cincinnati

    Cincinnati, Ohio, 45219, United States

  • University of Colorado Anschutz Medical Campus

    Aurora, Colorado, 80045, United States

  • University of Texas Southwestern Medical Center

    Dallas, Texas, 75390, United States

  • University of Virginia

    Charlottesville, Virginia, 22903, United States

  • Vanderbilt University Medical Center

    Nashville, Tennessee, 37232, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.